CaraCream/ChocoBase Study ending March 1!

[Anonymous]

I just wanted to give everyone here a heads-up that the study being conducted by the University of Missouri Hospital on children and infants who have previously been treated with a PPI with either CaraCream or ChocoBase will be closed to enrollment on March 1, 2006. Participation in this simple survey study allows parents who have previously used either ChocoBase or CaraCream as a suspension for a PPI for any of their children to continue to purchase these products from Reflux Solutions until the study ends in December, 2006. If you have not already enrolled in this study but are interested in doing so, please visit http://www.marci-kids.com/1043459.html or call Rene Blagg at (573) 884-4112 for more information.

[Anonymous]

For those who are not familiar with ChocoBase and CaraCream, they are buffered, flavored suspension agents used for making stable liquid compounds of PPIs such as Prevacid and Prilosec and designed for pediatric use. They were created by Dr Jeffrey Phillips and are sold by the University of Missouri – Columbia. In the United States they are only available to participants in the study conducted by the University of Missouri mentioned above. This is due to a non-compete agreement with Santarus Inc., the makers of Zegerid Powder for Oral Suspension, which is a similar product that already contains the PPI omeprazole. We highly recommend the use of Zegerid for infants and children.

ChocoBase and CaraCream are still available for retail sale outside of the US. For more information, email: [email protected].

RefluxSol2006-2-6 15:39:48

[Author]

Posts